GlassScriptPhysician profile
Robert James Fox
NPI 1427576297
$17,850.32
in general payments reported to CMS, 2019-2025
62 companies · $2,630 in 2025
The $2,630 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,154 · 2022: $3,076 · 2023: $6,228 · 2024: $4,763 · 2025: $2,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $2,283 · Education: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,033.86 |
| Travel and Lodging | $2,283.40 |
| Education | $302.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $2,725.32 | 2021-2023 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Inspire Medical Systems, INC. | $2,423.52 | 2023-2025 | Inspire |
| Ucb, INC. | $1,402.96 | 2021-2025 | Fintepla, Briviact, Rystiggo |
| Abbvie INC. | $1,200.27 | 2021-2025 | |
| Sk Life Science, INC. | $872.91 | 2021-2025 | Xcopri |
| Lilly USA, LLC | $713.73 | 2022-2025 | Emgality, Amyvid, Kisunla |
| Jazz Pharmaceuticals INC. | $678.20 | 2021-2025 | |
| Biogen, INC. | $629.31 | 2021-2025 | Tysabri, Vumerity, Skyclarys |
| Pfizer INC. | $602.37 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $580.44 | 2021-2024 | Ultomiris, Soliris |
| Lundbeck LLC | $541.43 | 2021-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $491.16 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $456.15 | 2021-2025 | |
| Neurelis, INC. | $429.40 | 2022-2025 | Valtoco |
| Mdd US Operations, LLC | $275.00 | 2022-2024 | Gocovri |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $270.98 | 2023-2024 | Purified Cortrophin Gel |
| Eisai INC. | $219.27 | 2023-2025 | |
| Amgen INC. | $194.47 | 2021-2025 | Uplizna, Aimovig |
| Harmony Biosciences LLC | $184.68 | 2021-2025 | Wakix |
| Catalyst Pharmaceuticals, INC. | $171.35 | 2021-2025 | Firdapse |
| Csl Behring | $170.66 | 2021-2023 | Hizentra |
| Tanabe Pharma America, INC. | $166.28 | 2021-2025 | Radicava |
| Tg Therapeutics, INC. | $149.58 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $132.01 | 2022 | |
| Emd Serono, INC. | $126.71 | 2023-2025 | Mavenclad |
| Genentech USA, INC. | $122.93 | 2023-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Kyowa Kirin, INC. | $121.12 | 2021-2024 | Nourianz |
| Amneal Pharmaceuticals LLC | $120.52 | 2023-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Zogenix INC. | $120.25 | 2021 | |
| Neurocrine Biosciences, INC. | $110.90 | 2021-2025 | Ingrezza, Ongentys |
| Allergan, INC. | $105.73 | 2021-2022 | |
| Argenx US, INC. | $99.59 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Genzyme Corporation | $98.54 | 2021-2025 | |
| Axsome Therapeutics, INC. | $94.20 | 2023-2025 | Sunosi, Symbravo |
| Abbott Laboratories | $88.91 | 2021-2025 | Infinity |
| Sumitomo Pharma America, INC. | $73.99 | 2023-2024 | Aptiom |
| Astrazeneca Pharmaceuticals LP | $71.24 | 2024-2025 | Wainua |
| Sunovion Pharmaceuticals INC. | $60.33 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $56.91 | 2022-2023 | Trudhesa |
| Acadia Pharmaceuticals INC | $54.76 | 2024-2025 | Nuplazid |
| Merz Pharmaceuticals, LLC | $50.88 | 2023-2025 | Xeomin, Ampyra, Inbrija |
| Cycle Pharmaceuticals INC | $47.01 | 2025 | Tascenso Odt, Bafiertam |
| Celgene Corporation | $43.97 | 2022-2024 | Zeposia |
| Janssen Pharmaceuticals, INC | $41.29 | 2021-2022 | |
| Ge Healthcare | $39.65 | 2025 | |
| Currax Pharmaceuticals LLC | $38.28 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $36.05 | 2023-2024 | Nuedexta |
| Acorda Therapeutics, INC | $32.29 | 2023 | Inbrija, Ampyra |
| E.R. Squibb & Sons, L.L.C. | $32.00 | 2025 | Zeposia |
| Mallinckrodt Hospital Products INC. | $30.31 | 2025 | Acthar |
| Microtransponder, INC. | $27.48 | 2024 | |
| Aquestive Therapeutics, INC. | $26.91 | 2025 | |
| Boston Scientific Corporation | $26.11 | 2024 | Watchman Access System |
| Nevro Corp. | $22.11 | 2021 | |
| Banner Life Sciences, LLC | $21.13 | 2021 | |
| Arbor Pharmaceuticals, INC. | $21.02 | 2021 | |
| Upsher-Smith Laboratories LLC | $19.95 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.07 | 2023 | Keveyis |
| Corium, LLC | $18.10 | 2023 | Adlarity |
| Biohaven Pharmaceuticals, INC. | $17.45 | 2021 | |
| Immedica Pharma US, INC. | $16.33 | 2023 | |
| Medtronic, INC. | $14.85 | 2023 | Percept PC Brainsense |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.